FDA Approves First Treatment for Common Kidney Disease Breakthrough Therapy Could Help Millions at Risk of Kidney Failure The FDA has granted accelerated approval to Voyxact (sibeprenlimab-szsi), the first treatment specifically designed for IgA nephropathy, the most common form of kidney disease worldwide. The breakthrough offers new hope for patients